COLLABORATION

Farrer Park Hospital Launches

Clinical Collaboration with ARC Hospitals

Farrer Park Hospital announced the launch of a clinical collaboration with Allegiant Regional Care (ARC) Hospitals to promote continuing medical education among specialists and physicians.

The collaboration was officially launched at a joint surgical conference held at Cebu, Philippines on 11 February.

The conference marked the start of the two healthcare providers’ plans to cooperate on improving patient care and promoting clinical innovation.

In Lapu-Lapu City, Cebu, ARC Healthcare manages a 100-bed medical facility. Dr. Alex. E. Alegrado, the provider's medical director, explained that holding the conference would advance the medical education of the affiliated physicians of ARC Hospitals by allowing them to hear from eminent and reputable specialists from FPH.

Dr. Melissa Teo, a surgical oncologist from FPH, discussed advancements in melanoma, sarcoma, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC) during the conference.

Fda Approval

Anavasi Diagnostics Receives FDA EUA for AscencioDx Covid-19 Test

According to Anavasi Diagnostics, the FDA has now granted the AscencioDx® COVID-19 Test and The AscencioDx® Molecular Analyzer an Emergency Use Permit (EUA).

The AscencioDx® COVID-19 test yields findings for the detection of SARS-CoV-2 RNA. The AscencioDx system's portability and affordability make it possible to perform high-quality point-of-care molecular testing in a variety of healthcare settings, including facilities like urgent care facilities, mobile testing locations, assisted living facilities, and more.

The test reduces the possibility of missing a novel strain by targeting numerous areas of the viral genome using proprietary assay chemistry. The AscencioDx proprietary platform will also facilitate quick product development for new viral and bacterial targets, such as strains linked to sexual health, RSV, influenza, and more.

Contrary to more expensive and complex PCR testing, the AscencioDx Molecular Detector's proprietary compact design uses RT-LAMP (reverse transcription loop-mediated isothermal amplification) technology and doesn't require sending a sample to a different location or waiting days for results.

The AscencioDx Molecular Detector and COVID-19 Test generate less biowaste because the detector can be used for at least 3,000 test rounds. It doesn't require batteries or other electrical components to be discarded after use, unlike the majority of single-use molecular tests.

Compared to other molecular POC tests, the AscencioDx system comes with less packing and disposable parts.